Clinical trial
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
NCT03009981
Study timeline
Study start (actual)2017-03-06Date precision: day
Registry last updated2025-12-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Prostate Cancerunresolved
Interventions
ApalutamideDRUG · verified · RxNorm: apalutamide
LHRH AnalogueDRUG
Abiraterone AcetateDRUG · verified · RxNorm: abiraterone acetate
PrednisoneDRUG · verified · RxNorm: prednisone
Sponsors & collaborators
Alliance Foundation Trials, LLC.lead sponsor
Janssen Research & Development, LLCcollaborator
Mapped research locations
New YorkNew York, United States3ChicagoIllinois, United States2San DiegoCalifornia, United States2PortlandOregon, United States2Washington D.C.District of Columbia, United States2AlbuquerqueNew Mexico, United States2BuffaloNew York, United States2HoustonTexas, United States1BostonMassachusetts, United States1St LouisMissouri, United States1San FranciscoCalifornia, United States1PittsburghPennsylvania, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03009981 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.